EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective

Leila Amini, Jaspal Kaeda, Enrico Fritsche, Andy Roemhild, Daniel Kaiser, Petra Reinke

Frontiers in Cell and Developmental Biology · 30.01.2023 · 10

DOI: 10.3389/fcell.2022.1081644 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 30.01.2023. Verfasst von Leila Amini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Berlin Center for Advanced Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rejection of solid organ transplant and graft versus host disease (GvHD) continue to be challenging in post transplantation management. The introduction of calcineurin inhibitors dramatically improved recipients’ short-term prognosis. However, long-term clinical outlook remains poor, moreover, the lifelong dependency on these toxic drugs leads to chronic deterioration of graft function, in particular the renal function, infections and de-novo malignancies. These observations led investigators to identify alternative therapeutic options to promote long-term graft survival, which could be used concomitantly, but preferably, replace pharmacologic immunosuppression as standard of care. Adoptive T cell (ATC) therapy has evolved as one of the most promising approaches in regenerative medicine in the recent years. A range of cell types with disparate immunoregulatory and regenerative properties are actively being investigated as potential therapeutic agents for specific transplant rejection, autoimmunity or injury-related indications. A significant body of data from preclinical models pointed to efficacy of cellular therapies. Significantly, early clinical trial observations have confirmed safety and tolerability, and yielded promising data in support of efficacy of the cellular therapeutics. The first class of these therapeutic agents commonly referred to as advanced therapy medicinal products have been approved and are now available for clinical use. Specifically, clinical trials have supported the utility of CD4 + CD25+FOXP3+ regulatory T cells (Tregs) to minimize unwanted or overshooting immune responses and reduce the level of pharmacological immunosuppression in transplant recipients. Tregs are recognized as the principal orchestrators of maintaining peripheral tolerance, thereby blocking excessive immune responses and prevent autoimmunity. Here, we summarize rationale for the adoptive Treg therapy, challenges in manufacturing and clinical experiences with this novel living drug and outline future perspectives of its use in transplantation.

Schlagwörter

Stichwörter der Autor:innen

adoptive regulatory T cell therapyadvanced medicinal therapeutic productsclinical trialsimmune regulationregenerative medicine

Autor:innen und Institutionen

  • Berlin Center for Advanced Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Berlin Institute of Health-Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Förderung

  • H2020 Health

Zitieren

APA

Amini, L., Kaeda, J., Fritsche, E., Roemhild, A., Kaiser, D., & Reinke, P. (2023). Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective. Frontiers in Cell and Developmental Biology, 10. https://doi.org/10.3389/fcell.2022.1081644

Vancouver

Amini L, Kaeda J, Fritsche E, Roemhild A, Kaiser D, Reinke P. Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective. Frontiers in Cell and Developmental Biology. 2023;10. doi:10.3389/fcell.2022.1081644

BibTeX
@article{Amini2023,
  author = {Amini, Leila and Kaeda, Jaspal and Fritsche, Enrico and Roemhild, Andy and Kaiser, Daniel and Reinke, Petra},
  title = {Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2023},
  volume = {10},
  doi = {10.3389/fcell.2022.1081644}
}
Kostenlos starten →